Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Abbott
ClinicalTrials.gov Identifier:
NCT00526617
First received: September 5, 2007
Last updated: January 12, 2012
Last verified: January 2012

September 5, 2007
January 12, 2012
August 2007
June 2010   (final data collection date for primary outcome measure)
  • Maximum Tolerated Dose [ Time Frame: Duration of Study ] [ Designated as safety issue: Yes ]
  • Safety and Tolerability [ Time Frame: Duration of Study ] [ Designated as safety issue: Yes ]
  • Pharmacokinetic Profile [ Time Frame: Duration of Study ] [ Designated as safety issue: Yes ]
Maximum Tolerated Dose [ Time Frame: 6 Months ]
Complete list of historical versions of study NCT00526617 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
A Phase I Study of ABT-888 in Combination With Temozolomide (TMZ) in Subjects With Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM)

This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma (HCC).

A Phase 1, multicenter, dose-escalation study evaluating the safety and tolerability of the PARP inhibitor ABT-888 in combination with Temozolomide (TMZ) in subjects with non-hematologic malignancies (NHM), including metastatic melanoma (MM), BRCA deficient breast, ovarian, primary peritoneal, or fallopian tube cancer, and hepatocellular carcinoma (HCC).

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Non-hematologic Malignancies
  • Metastatic Melanoma
  • Breast Cancer
  • Ovarian Cancer
  • Primary Peritoneal Cancer
  • Fallopian Tube Cancer
  • Hepatocellular Carcinoma
  • Drug: ABT-888
    Oral capsules
    Other Name: ABT-888
  • Drug: Temozolomide
    Oral capsules
    Other Names:
    • Temozolomide
    • Temodar
    • TMZ
Experimental: Open Label
Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
Interventions:
  • Drug: ABT-888
  • Drug: Temozolomide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
41
Not Provided
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

Dose escalation and expanded safety cohorts

  • Evaluable disease, histologically confirmed malignancy (metastatic or unresectable) and standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective
  • ECOG Performance Score less than or equal to 2
  • Adequate hematologic, renal and hepatic function
  • Normal sodium, calcium and magnesium levels
  • Voluntarily signed informed consent

Expanded Safety Cohorts Only

  • Population:
  • Metastatic melanoma (MM)
  • Hepatocellular carcinoma (HCC) Child Pugh Category A and B classification only
  • BRCA deficient tumor status*: advanced breast cancer (with soft tissue disease), or advanced ovarian cancer, or advanced primary peritoneal cancer, or advanced fallopian tube cancer*

    *Patients must have histologically or cytologically confirmed solid tumors with a positive genetic test result documenting BRCA 1 or BRCA 2 mutation status, to be considered eligible.

  • Serial tumor biopsies: Required for all subjects enrolled in one of the Expanded Low Dose Safety Cohorts.

Exclusion Criteria:

Dose Escalation and Expanded Safety Cohorts

  • Known central nervous system (CNS) metastases or CNS primary cancer.
  • Previous or current malignancies at other sites, except: adequately treated in situ carcinoma of cervix uteri; basal/squamous cell carcinoma of skin; previous malignancy considered cured.
  • Previous history or current seizure disorder.
  • Clinically significant and uncontrolled major medical condition(s) or any medical condition that places the subject at an unacceptably high risk for toxicities.
  • Transplant recipients and patients receiving combination anti-retroviral therapy for HIV due to the use of immunosuppressant therapies.
  • Lactating or pregnant female.
  • Chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy will not be allowed within either 4 weeks, or 5 half lives of a targeted therapy prior to study drug administration (Study Day 1).
  • Prior therapy with regimens containing dacarbazine (DTIC) or TMZ is not permitted.
  • Anti-cancer therapy is not permitted during the treatment portion of the study.
  • Hormone therapy, bisphosphonates or LHRH-agonists for prostate cancer are permitted prior to and during the study.
  • Significant adverse event or toxicity due to previous anti-cancer treatment that has not recovered to within one grade level (not to exceed Grade 2) of baseline.

Expanded Safety Cohorts Only:

  • MM Only: Prior treatment with DNA damaging agents or cytotoxic chemotherapy including carboplatin, cisplatin, fotemustine, paclitaxel, vincristine, TMZ and DTIC.
  • Prior therapy with biologic agents (including IL-2, interferon, bevacizumab, vaccines and immunostimulants) and signal transduction inhibitors (including sorafenib, erlotinib, sutent and elesclomol) are allowed.

Lower Dose Expanded Safety Cohorts Only

  • Anti-coagulant restrictions for subjects that have tumor biopsies.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00526617
M06-862
No
Abbott
Abbott
Not Provided
Study Director: Bhardwaj Desai, MD Abbott
Abbott
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP